Targeting Innate Immunity for HCV Antiviral Therapy
Michael Gale and Jr.
from: Hepatitis C: Antiviral Drug Discovery and Development (Edited by: Seng-Lai Tan and Yupeng He). Caister Academic Press, U.K. (2011)
The ability of HCV to mediate persistent, life-long infection in its human host is linked to a poor response rate to the current interferon-based therapy for treatment of infection. Future antiviral therapy against HCV protein products will most certainly be met with challenges due to virus resistance. Molecular studies of HCV-host interactions have revealed how innate immune programs of the host can suppress HCV infection and support immune amplification. Therapeutic strategies to target these host features and factors may provide potent new approaches to HCV treatment through immune enhancement while minimizing the likelihood that HCV will resist such actions read more ...